S. Andrew

8.4k citations

84 papers · 4.2k indexed · 1 hit paper · h-index 34

Impact in

Genetics top 0.5%
- Glioma Diagnosis and Treatment
Cancer Research top 2%
- Cancer, Hypoxia, and Metabolism

Papers in ⓘ

Genetics 58
- Glioma Diagnosis and Treatment 58
Cancer Research 24
- Cancer, Hypoxia, and Metabolism 13
- Cancer Genomics and Diagnostics 11

Co-authors: Tracy T. Batchelor (35 shared papers)B Bernstein (4 shared papers)Richard P. Koche (2 shared papers)Manching Ku (2 shared papers)Eric M. Mendenhall (2 shared papers)Patrick Y. Wen (21 shared papers)A. John Iafrate (13 shared papers)Daniel P. Cahill (17 shared papers)
Journals: Journal of Clinical Oncology (17 papers)Clinical Cancer Research (6 papers)Journal of Neuro-Oncology (6 papers)Neuro-Oncology (5 papers)Cancer Research (3 papers)
Partner nations: United States Japan Netherlands

In The Last Decade

S. Andrew

84 papers receiving 4.2k citations

Hit Papers

align trajectories log scale

Genomewide Analysis of PRC1 and PRC2 Occupancy Identifies Two Classes of Bivalent Domains 2008 · 787 citations

Peers

Countries citing papers authored by S. Andrew

Since Specialization

Citations

This map shows the geographic impact of S. Andrew's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Andrew with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Andrew more than expected).

Fields of papers citing papers by S. Andrew

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Andrew. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Andrew. The network helps show where S. Andrew may publish in the future.

Co-authors

The 25 scholars most cited alongside S. Andrew, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with S. Andrew Line = papers co-authored together S. Andrew links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 84 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Genomewide Analysis of PRC1 and PRC2 Occupancy Identifies Two Classes of Bivalent Domains PLoS Genetics ·Manching Ku, Richard P. Koche, Esther Rheinbay, Eric M. Mendenhall, Mitsuhiro Endoh, Tarjei S. Mikkelsen, Aviva Presser, Chad Nusbaum, Xiaohui Xie, S. Andrew, Mazhar Adli, Simon Kasif, Leon M. Ptaszek, Chad A. Cowan, Eric S. Lander, Haruhiko Koseki, B Bernstein Hit paper breakdown →	2008	787
2	GC-Rich Sequence Elements Recruit PRC2 in Mammalian ES Cells PLoS Genetics ·Eric M. Mendenhall, Richard P. Koche, Thanh Tung Truong, Vicky W. Zhou, Biju Issac, S. Andrew, Manching Ku, B Bernstein	2010	322
3	T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project Clinical Cancer Research ·Sohil H. Patel, Laila Poisson, Daniel J. Brat, Yueren Zhou, Lee Cooper, Matija Snuderl, Cheddhi Thomas, Ana M. Franceschi, Brent Griffith, Adam E. Flanders, John G. Golfinos, S. Andrew, Rajan Jain	2017	283
4	Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression Cancer Discovery ·James P. Sullivan, Brian V. Nahed, Marissa W. Madden, Samantha M. Oliveira, Simeon Springer, Deepak Bhere, S. Andrew, Hiroaki Wakimoto, S. Michael Rothenberg, Lecia V. Sequist, Ravi Kapur, Khalid Shah, A. John Iafrate, William T. Curry, Jay S. Loeffler, Tracy T. Batchelor, David N. Louis, Mehmet Toner, Shyamala Maheswaran, Daniel A. Haber	2014	200
5	An Aberrant Transcription Factor Network Essential for Wnt Signaling and Stem Cell Maintenance in Glioblastoma Cell Reports ·Esther Rheinbay, Mario L. Suvà, Shawn Gillespie, Hiroaki Wakimoto, Anoop P. Patel, Mohd Shahid, Ozgur Oksuz, Samuel D. Rabkin, Robert L. Martuza, Miguel N. Rivera, David N. Louis, Simon Kasif, S. Andrew, B Bernstein	2013	197
6	Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH -Mutant Gliomas Clinical Cancer Research ·Hiroaki Wakimoto, Shota Tanaka, William T. Curry, Franziska Loebel, Dan Zhao, Kensuke Tateishi, Juxiang Chen, Lindsay K. Klofas, Nina Lelic, James C. Kim, Dora Dias‐Santagata, Leif W. Ellisen, Darrell R. Borger, Sarah‐Maria Fendt, Matthew G. Vander Heiden, Tracy T. Batchelor, A. John Iafrate, Daniel P. Cahill, S. Andrew	2014	130
7	Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib Journal of Thoracic Oncology ·Justin F. Gainor, Carol A. Sherman, Kathryn Willoughby, Jennifer Logan, Elizabeth A. Kennedy, Priscilla K. Brastianos, S. Andrew, Alice T. Shaw	2015	125
8	Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy eLife ·Xin Cui, Chao Ma, Varshini Vasudevaraja, Jonathan Serrano, Jie Tong, Yansong Peng, Michael DeLorenzo, Guomiao Shen, Joshua D. Frenster, Renee‐Tyler T. Morales, Weiyi Qian, Aristotelis Tsirigos, S. Andrew, Rajan Jain, Sylvia C. Kurz, Erik P. Sulman, Dimitris G. Placantonakis, Matija Snuderl, Weiqiang Chen	2020	123
9	Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma Clinical Cancer Research ·Kensuke Tateishi, A. John Iafrate, Quan Ho, William T. Curry, Tracy T. Batchelor, Keith T. Flaherty, Maristela L. Onozato, Nina Lelic, Sudhandra Sundaram, Daniel P. Cahill, S. Andrew, Hiroaki Wakimoto	2016	119
10	Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate Clinical Cancer Research ·Ovidiu C. Andronesi, Franziska Loebel, Wolfgang Bogner, Małgorzata Marjańska, Matthew G. Vander Heiden, A. John Iafrate, Jörg Dietrich, Tracy T. Batchelor, Elizabeth R. Gerstner, William G. Kaelin, S. Andrew, Bruce R. Rosen, Daniel P. Cahill	2015	116
11	A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma Oncotarget ·Isabel Arrillaga‐Romany, S. Andrew, Joshua E. Allen, Wolfgang Oster, Patrick Y. Wen, Tracy T. Batchelor	2017	108
12	Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate Nature Communications ·Ovidiu C. Andronesi, Isabel Arrillaga‐Romany, Ina Ly, Wolfgang Bogner, Eva Ratai, Kara Reitz, A. John Iafrate, Jörg Dietrich, Elizabeth R. Gerstner, S. Andrew, Bruce R. Rosen, Patrick Y. Wen, Daniel P. Cahill, Tracy T. Batchelor	2018	99
13	Angiogenesis as a Therapeutic Target in Malignant Gliomas The Oncologist ·S. Andrew, A. Gregory Sorensen, Rakesh K. Jain, Tracy T. Batchelor	2009	94
14	“Real world” use of a highly reliable imaging sign: “T2-FLAIR mismatch” for identification of IDH mutant astrocytomas Neuro-Oncology ·Rajan Jain, Derek R. Johnson, Sohil H. Patel, Maurício Castillo, Marion Smits, Martin J. van den Bent, S. Andrew, Daniel P. Cahill	2020	87
15	Rapid Radiographic and Clinical Improvement After Treatment of a MET-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor Journal of Clinical Oncology ·S. Andrew, Tracy T. Batchelor, Eunice L. Kwak, Jeffrey W. Clark, Daphne L. Wang, Keith D. Wilner, David N. Louis, A. John Iafrate	2011	83
16	Prevalence and pattern of gluteus medius and minimus tendon pathology and muscle atrophy in older individuals using MRI Skeletal Radiology ·S. Andrew, Suzanne S. Long, Adam C. Zoga, Paul Read, Diane M. Deely, Laurence Parker, William B. Morrison	2015	74
17	The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1 -Mutant Cancers and Potentiates NAD+ Depletion–Mediated Cytotoxicity Cancer Research ·Kensuke Tateishi, Fumi Higuchi, Julie J. Miller, Mara V.A. Koerner, Nina Lelic, Ganesh M. Shankar, Shota Tanaka, David E. Fisher, Tracy T. Batchelor, A. John Iafrate, Hiroaki Wakimoto, S. Andrew, Daniel P. Cahill	2017	73
18	Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma Journal of Neuro-Oncology ·Jayashree Kalpathy–Cramer, Vyshak Chandra, Xiao Da, Yangming Ou, Kyrre E. Emblem, Alona Muzikansky, Xuezhu Cai, Linda Douw, J.G. Evans, Jörg Dietrich, S. Andrew, Patrick Y. Wen, Stephen Stufflebeam, Bruce R. Rosen, Dan G. Duda, Rakesh K. Jain, Tracy T. Batchelor, Elizabeth R. Gerstner	2016	62
19	First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M–mutant pediatric diffuse intrinsic pontine glioma: a case report Journal of Neurosurgery Pediatrics ·Matthew D. Hall, Yazmín Odia, Joshua E. Allen, Rohinton S. Tarapore, Ziad Khatib, Toba N. Niazi, Doured Daghistani, Lee Schalop, S. Andrew, Wolfgang Oster, Minesh P. Mehta	2019	60
20	Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer Relapsing on Standard Dose Alectinib Journal of Thoracic Oncology ·Justin F. Gainor, S. Andrew, Jennifer Logan, Ranliang Hu, Kevin Oh, Priscilla K. Brastianos, Helen A. Shih, Alice T. Shaw	2015	57

About S. Andrew

S. Andrew is a scholar working on Genetics, Cancer Research, Radiology, Nuclear Medicine and Imaging, Oncology and Neurology, having authored 84 papers that have together received 4.2k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (58 papers), Cancer, Hypoxia, and Metabolism (13 papers), Cancer Genomics and Diagnostics (11 papers), Cancer Cells and Metastasis (9 papers), Histone Deacetylase Inhibitors Research (9 papers), Radiomics and Machine Learning in Medical Imaging (8 papers), Brain Metastases and Treatment (7 papers) and Neuroblastoma Research and Treatments (7 papers). The work is most often cited by research in Genetics (1.6k citations), Cancer Research (885 citations), Molecular Biology (2.2k citations), Oncology (741 citations) and Radiology, Nuclear Medicine and Imaging (612 citations). S. Andrew has collaborated with scholars based in United States, Japan and Netherlands. Frequent co-authors include Tracy T. Batchelor, B Bernstein, Richard P. Koche, Manching Ku, Eric M. Mendenhall, Patrick Y. Wen, A. John Iafrate, Daniel P. Cahill, Simon Kasif and Esther Rheinbay. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Journal of Neuro-Oncology, Neuro-Oncology and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact